BRAF and melanoma: In patients treated with anti‐PD1 monotherapy (n = 76), those with BRAF V600 mutations (n = 9) had a significantly shorter RFS (p < 0.0001, Figure 3b) and an increased hazard of recurrence (HR 5.4, CI: 2.2–14.0, p < 0.001) compared to patients with BRAF WT melanomas treated with anti‐PD1 (n = 64).